| Project/Area Number |
16K09474
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Cardiovascular medicine
|
|---|
| Research Institution | Nagasaki University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
池田 聡司 長崎大学, 医歯薬学総合研究科(医学系), 講師 (10336159)
前村 浩二 長崎大学, 医歯薬学総合研究科(医学系), 教授 (90282649)
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 肺動脈性肺高血圧症 / バイオマーカ / micro RNA / microRNA / アポトーシス / 膠原病性肺高血圧症 / biomarker / 臨床血管学 |
|---|
| Outline of Final Research Achievements |
Pulmonary arterial hypertension(PAH) is a frequent complication in connective tissue diseases (CTD) and is associated with a high degree of mortality. Micro RNAs(miRNAs) function in various cellular activities. However, the role of miRNA in connective tissue disease-pulmonary arterial hypertension (CTD-PAH) is not fully understood. We assessed the hypothesis that whether serum miRNA expression can serve as a novel biomarker of CTD-PAH and evaluates the possibility that miRNA is involved in the pathogenesis of CTD-PAH. The expression miR-4674 was increased in the patients with CTD-PAH. High miR-4674 expression correlated with mean PA pressure. Next, we investigated the gain and loss of miR-4674 function by analyzing the bioactivity of pulmonary arterial smooth muscle cells (hPASMC). miRNA-4674 increased cells proliferation and protect cells against apoptosis. Interference with this pathway may offer novel approaches to treating CTD-PAH.
|
| Academic Significance and Societal Importance of the Research Achievements |
肺動脈性肺高血圧症(PAH)は、昨今、新しい治療薬が開発されてはいるが、いまだ予後不良の疾患である。特に膠原病性肺動脈性肺高血圧症(CTD-PAH)の予後は非常に悪い。本研究結果はCTD-PAHの早期発見が可能となり、予後の改善が可能となる、また、既存の治療薬とは異なる、新しいPAHの治療ターゲットとなり得る事が示唆され、CTD-PAHの患者の予後をさらに改善することが期待できる。
|
